Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will issued 82,627 ordinary shares of 1 penny each (“Option Shares”) in settlement of options that have been exercised by a former employee. The options were exercised at a price of US $0.2088 per ordinary share for total consideration of US $17,252.52.
Admission to trading on AIM (“Admission”) of the Option Shares, which will rank pari passu with the existing Ordinary Shares, has been applied for, and it is expected that Admission will become effective and dealings in the new Ordinary Shares will commence on 16 July 2015.
Total Voting Rights
Following Admission, the total issued share capital of the Company will be 64,321,069 Ordinary Shares with one voting right each. The Company does not hold any shares in treasury.
Accordingly, the total voting rights in the Company will be 64,321,069. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure and Transparency Rules of the UK Financial Conduct Authority.
Motif Bio plc
Graham Lumsden, Chief Executive Officer
Robert Bertoldi, Chief Financial Officer
Zeus Capital Limited (Nominated Advisor and Broker)
Phil Walker / Dan Bate
+44 (0) 20 3829 5000
Northland Capital Partners (Broker)
+44 (0) 207 382 1100
Plumtree Capital Limited (Financial Advisor)
+44 (0) 207 183 2493
Yellow Jersey PR
+44 (0) 7768 537 739
Notes to Editors
Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, iclaprim, in clinical development and MTF-001, a preclinical stage programme to design a best-in-class dihydrofolate reductase inhibitor (DHFRi).
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.